Answers are grounded in this paper and cite their sources.
In September 2022, deucravacitinib, the first oral, highly targeted, allosteric TYK2 inhibitor was approved in the United States and other countries for the treatment of moderate to severe psoriasis.Unlike other janus kinase (JAK) inhibitors which bind to the catalytic domain of tyrosine kinase, deucravacitinib binds to the regulatory domain, having little impact on JAK1, 2, or 3.At the time of its introduction, it was the most highly targeted oral agent to block the IL-17/ IL-23 axis of cytokines which we know cause psoriasis.1 It is that selectivity of deucravacitinib that contributes to its impressive safety.Deucravacitinib does not exhibit any of the adverse events associated with other JAK inhibitors and, as a result, it was approved without any boxed warnings, unlike the other JAK inhibitors which carry boxed warnings for cancer, infection, heart attacks, clotting, and death.The safety of deucravacitinib was reinforced by 4-year data with more than 4,300 patient-years in a long-term extension trial known as POETYK LTE.In that trial, incidence rates of adverse events decreased from year 1 to year 4. The only exception was the onset of the COVID-19 pandemic, and COVID-19 rates did not differ from the general population.Excluding COVID-19 infection, the rate of serious infections was lower at 4 years than during the 1 st year.
No takes yet. Share an insight, caveat, or question.
Karpoff et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: